Apheresis Market by Product (Device, Disposable), Procedure [Donor, Therapeutic (Neurological, Blood)], Application (Plasmapheresis, Plateletpheresis), Technology (Centrifugation, Membrane Separation), End User (Clinic) - Global Forecast to 2031

icon1
USD 4.41 BN
MARKET SIZE, 2031
icon2
CAGR 7.9%
(2026-2031)
icon3
500
REPORT PAGES
icon4
380
MARKET TABLES

APHERESIS MARKET SIZE, SHARE & GROWTH SNAPSHOT

apheresis-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global apheresis market is projected to grow from USD 3.02 billion in 2026 to USD 4.41 billion by 2031, at a CAGR of 7.9% during the forecast period. The market was valued at USD 2.81 billion in 2025. The growth of the apheresis market is driven by the rising number of cases of chronic diseases, autoimmune diseases, hematologic conditions, and neurological disorders, as well as an increased need for plasma products. The increasing use of advanced technologies in blood separation, the establishment of plasma centers, favorable government initiatives for blood donation programs, and technological advances in apheresis devices are contributing to market growth.

KEY TAKEAWAYS

  • BY REGION
    The Asia Pacific is anticipated to have the highest CAGR during the forecast period.
  • BY PRODUCT
    Apheresis disposables are expected to dominate the offering segment, with an 83.4% share in 2025.
  • BY TYPE
    Donor apheresis is expected to register the highest CAGR of 58.2% during the forecast period.
  • BY TECHNOLOGY
    Centrifugation is projected to hold 79.8% of the market during the forecast period.
  • COMPETITIVE LANDSCAPE (KEY PLAYERS)
    Major market players have adopted both organic and inorganic strategies, including partnerships and investments. For instance, Terumo Corporation (Japan), Fresenius SE & Co. KGaA (Germany), and Haemonetics Corporation (US) have entered into a number of agreements and partnerships to cater to the growing demand for apheresis across innovative applications.
  • COMPETITIVE LANDSCAPE (STARTUPS/SMES)
    Macopharma SA (France), Infomed SA (Switzerland), Therakos LLC (UK), and Haier Biomedical (China), among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.

The global apheresis market is experiencing steady growth, driven by rising rates of chronic diseases and autoimmune and hematological disorders, as well as rising demand for plasma-based treatments worldwide. New deals and developments, including strategic partnerships between healthcare service providers and medical equipment makers, investments in recycling technologies, and innovations in cell collection for cellular and genetic treatments, are reshaping the industry landscape.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The impact on consumers' business emerges from customer trends or disruptions. Blood collection centers, hospitals & transfusion centers, and other end users are clients of apheresis manufacturers, and patients requiring therapeutic apheresis and donors participating in blood component collection are clients of apheresis systems. Shifts, which are changing trends or disruptions, will impact the revenues of end users. The revenue impact on end users will affect the revenue of Blood collection centers, hospitals & transfusion centers, and other end users, which will further affect the revenues of apheresis manufacturers.

apheresis-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Rising prevalence of autoimmune and neurological disorders
  • Increasing Utilization of Plasma-Derived Biologics by Biopharmaceutical Companies
RESTRAINTS
Impact
Level
  • High Procedural and Operational Costs
  • Limited Adoption of Apheresis Donation Procedures in Emerging Economies
OPPORTUNITIES
Impact
Level
  • Adoption of Apheresis Procedures in Leukemia and Pediatric Patients
  • Growing Investments in Emerging Markets by Governments and Key Industry Players
CHALLENGES
Impact
Level
  • Risk of Procedure-Related Adverse Events and Donor Safety Concerns
  • Risk of Transfusion-Transmitted Infections and Inadequate Blood Screening Infrastructure in Emerging Countries

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Rising prevalence of autoimmune and neurological disorders driving demand for therapeutic apheresis procedures

The rising prevalence of autoimmune and neurological disorders is a key driver of the apheresis market. According to the National Institute of Allergy and Infectious Diseases (NIAID), an estimated 8% of the U.S. population had an autoimmune disease in 2025, including more than 80 different disorders, which can be chronic and may usually require long-term treatment, further increasing the demand for apheresis.

Restraint: High Procedural and Operational Costs Limiting Adoption of Apheresis Technologies

Despite their advantages, apheresis devices and disposables come with high production and processing costs. These costs are further escalated by complex manufacturing requirements, maintenance services, and lengthy regulation processes. Furthermore, inadequate reimbursement coverage in developing economies may constrain patient acceptance.

Opportunity: Adoption of Apheresis Procedures in Leukaemia and Paediatric Patients Creating Growth Opportunities for the Apheresis Market

Increased adoption of apheresis procedures among leukemia and pediatric patients is driving several growth prospects for the apheresis market. Therapeutic apheresis is increasingly used in the management of leukemias to reduce leukemic white blood cell counts in a short time. The use of therapeutic apheresis procedures in pediatric patients is also gradually increasing due to expanding applications in pediatric hematological disorders, autoimmune diseases, neurological disorders, and stem cell transplantation procedures.

Challenge: Risk of Procedure-Related Adverse Events and Donor Safety Concerns

Procedure-induced adverse effects and safety concerns with regard to the donor represent a significant issue facing the apheresis industry. Possible procedure-induced adverse effects include hypotension, citrate toxicity, allergic reaction, problems with accessing the blood vessels, electrolyte disturbances, and even infections that can occur during extended or repeated procedures. Plasma donors who receive plasma frequently may suffer from fatigue, hypocalcemia, bruises, and lower number of blood components.

APHERESIS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Manufactures donor blood collection and therapeutic apheresis equipment, such as Spectra Optia and Trima Accel, which facilitate the collection of plasma, platelets, and red blood cells in hospitals and blood donation centers. Ensures greater efficiency, safety, automation, and quality in the collection process of blood components, as well as provides an opportunity to collect high-quality plasma during shorter procedure times.
Supplies therapeutic apheresis devices and extracorporeal blood treatment systems for applications including plasma exchange, immunoadsorption, and renal care through the Fresenius Medical Care division. Provides more effective treatment of autoimmune and renal diseases, greater accuracy in procedures, and minimized complexity, as well as facilitates patient monitoring and overall procedure safety.
Designs technologies for automated blood and plasma collection for the use in donor apheresis and blood management in blood centers and hospitals around the world. Enables higher efficiency, greater donor safety and convenience, reduces the need for manual interventions, and optimizes the management of blood components and operations.
Manufactures membranes and therapeutic apheresis solutions for the selective removal of blood components and the purification of plasma in the course of treating autoimmune, neurological, and liver diseases. Allows more effective removal of certain blood components, enhances procedural effectiveness, reduces potential adverse effects, and facilitates plasma purification.
Produces extracorporeal blood treatment solutions and therapeutic apheresis products integrated with infusion therapies and critical care solutions for hospitals and specialty clinics. Increases the efficiency of treatment processes, ensures reliable blood processing and fluid management, and improves overall treatment results.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The apheresis market operates within a complex interconnected ecosystem, which includes product innovation, regulatory oversight, manufacturing, distribution, and end-user adoption across multiple care settings. At the core of the ecosystem are manufacturers, which include Terumo Corporation (Japan), Fresenius SE & Co. KGaA (Germany), and Haemonetics Corporation (US). They are supported by academic institutes, clinical research bodies, and technology partners. Surrounding this network are regulatory agencies such as the Food and Drug Administration (FDA), European Medicines Agency (EMA), and national health authorities that enforce strict compliance with device safety, sterility, performance standards, and post-market surveillance. Downstream, the ecosystem culminates with diverse end users, including blood collection centers and blood component providers, hospitals & transfusion centers, and other end users whose clinical needs, workflow requirements, and safety priorities directly shape product selection, adoption rates, and long-term technology evolution within the market.

apheresis-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

apheresis-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Apheresis Market, By Type

By type, the apheresis market is classified into donor apheresis and therapeutic apheresis. Of these, the donor apheresis segment is expected to exhibit the highest CAGR over the forecast period, driven by rising global demand for plasma and blood derivatives, increasing awareness of voluntary blood donations, and the growing need for source plasma to produce plasma-derived products. Furthermore, innovation in automated donor apheresis equipment has improved collection efficiency, reduced processing time, and enhanced donor safety and convenience, leading to increased adoption by blood banks and plasma centers.

Apheresis Market, By Procedure

In 2025, plasmapheresis dominated the apheresis market, driven by the increasing number of patients suffering from autoimmune diseases, neurologic diseases, hematologic and renal disorders, which require the application of plasma exchange procedures. Moreover, advanced technologies in plasmapheresis procedures, such as automated plasma separation, efficient plasma collection, rapid procedures, and donor safety, are further fueling the demand for apheresis.

Apheresis Market, By Technology

In 2025, the centrifugation segment dominated the global apheresis market. The growing popularity of the centrifugation technique, driven by high efficiency in separating blood components, is expected to contribute significantly towards the growth of the apheresis segment. The growth of this segment is further supported by its ability to process large blood volumes with high precision and flexibility, making it highly preferred in blood banks, hospitals, and plasma collection centers.

REGION

Asia Pacific to be the fastest-growing region in global apheresis during the forecast period

The Asia Pacific is emerging as one of the most dynamic regions in the global apheresis market and is expected to witness the fastest growth rate over the coming years. This momentum is being driven by a combination of structural and behavioral shifts across the region. Healthcare systems in many APAC countries are evolving, with governments and private players investing heavily in infrastructure, advanced medical technologies, and specialized treatment capabilities. Emerging economies such as China and India are not only investing in healthcare modernization but are also seeing a growing patient pool and increasing demand for advanced therapies that rely on apheresis. Together, these factors are creating a strong foundation for sustained market expansion.

apheresis-market Region

APHERESIS MARKET: COMPANY EVALUATION MATRIX

In the apheresis market matrix, Terumo Corporation (Star) leads with a strong market share and extensive product footprint, driven by its advanced equipment and technologies. Kaneka Corporation (Emerging Leader) is gaining visibility with its specialized blood purification and adsorption-based therapeutic apheresis solutions, strengthening its position through innovation and niche clinical applications.

apheresis-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2025 (Value) USD 2.81 Billion
Market Forecast in 2026 (Value) USD 3.02 Billion
Market Forecast in 2031 (Value) USD 4.41 Billion
Growth Rate CAGR of 7.9% from 2026-2031
Years Considered 2024-2031
Base Year 2025
Forecast Period 2026-2031
Units Considered Value (USD Million/Billion), Volume (Units)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered
  • By Product:
    • Apheresis Devices
    • Apheresis Disposables
  • By Type:
    • Donor Apheresis
    • Therapeutic Apheresis
  • By Procedure:
    • Plasmapheresis
    • Plateletpheresis
    • Erythrocytapheresis
    • Leukapheresis
    • Photopheresis
    • Other Procedures
  • By Technology:
    • Centrifugation
    • Membrane Separation
  • By End User:
    • Blood Collection Centers & Blood Component Providers
    • Hospitals & Transfusion Centers
    • Other End Users
Regions Covered North America, Asia Pacific, Europe, South America, Middle East & Africa

WHAT IS IN IT FOR YOU: APHERESIS MARKET REPORT CONTENT GUIDE

apheresis-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Product Analysis In-depth assessment of apheresis by product (disposable, reusable), type (donor apheresis, therapeutic apheresis), procedure (plasmapheresis, plateletpheresis, leukapheresis, erythrocytapheresis, other procedures), technology (centrifugation, membrane separation), along with evaluation of automation capabilities, donor/patient safety features, and procedure efficiency
  • Analysis of emerging trends, including automated and connectivity features in apheresis devices
  • Advanced apheresis methods for the specific components in blood
  • Membranes for therapeutic apheresis
  • Advancements in digital management to enhance efficiency and clinical effectiveness of the procedures
Company Information Comprehensive profiles of leading global players such as Terumo Corporation, Haemonetics Corporation, Fresenius SE & Co. KGaA, Asahi Kasei Medical Co., Ltd., B. Braun SE, Kaneka Corporation, and other Partners
  • Collaboration strategies among hospitals, healthcare facilities, blood banks, and device makers
  • Developments in plasma collection facilities
  • Regulatory developments
  • Launches of new products
  • Innovations in automated and membrane-based apheresis
  • Collaborations/mergers driving innovation and efficiency
Geographic Analysis Region- and country-level demand mapping across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa; evaluation of regulatory frameworks, biologics adoption, pricing dynamics, and healthcare infrastructure
  • Region-wise market outlook emphasizing growth opportunities offered by the growing incidences of autoimmune, neurological, hematological, and renal diseases
  • Growing demand for blood products and plasma-derived products
  • Growing usage of apheresis procedures for therapeutic as well as for donor applications
  • Growing infrastructure for plasma and blood collection/transfusion services
  • Increased use of cell and gene therapies, among other factors

RECENT DEVELOPMENTS

  • October 2025 : Miltenyi Biotec and MiLaboratories collaborated to enhance the development of next-generation cell and gene therapies through a synergistic combination of bioinformatics, immune-profiling, and analytics software technologies, along with cell processing and therapy technologies of Miltenyi Biotec.
  • December 2024 : In partnership with Ori Biotech, Fresenius Kabi has made progress on providing scalable manufacturing capabilities for cell and gene therapy via automation and manufacturing technology.
  • November 2023 : Japan Medical Device Technology Co., Ltd. was acquired by Kaneka Corporation as part of a move towards strengthening its business operations within the area of medical devices in order to grow its Healthcare Solutions Unit.

 

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
 
 
30
2
EXECUTIVE SUMMARY
 
 
 
 
 
37
3
PREMIUM INSIGHTS
 
 
 
 
 
42
4
MARKET OVERVIEW
Apheresis market growth fueled by rising demand, technological advances, and expanding cell therapy adoption.
 
 
 
 
 
45
 
4.1
INTRODUCTION
 
 
 
 
 
 
4.2
MARKET DYNAMICS
 
 
 
 
 
 
 
4.2.1
DRIVERS
 
 
 
 
 
 
 
4.2.1.1
RISING PREVALENCE OF AUTOIMMUNE AND NEUROLOGICAL DISORDERS DRIVING DEMAND FOR THERAPEUTIC APHERESIS PROCEDURES
 
 
 
 
 
 
4.2.1.2
RISING DEMAND FOR BLOOD COMPONENTS AND INCREASING EMPHASIS ON TRANSFUSION SAFETY TO SUPPORT MARKET EXPANSION
 
 
 
 
 
 
4.2.1.3
GROWING VOLUME OF COMPLEX ONCOLOGICAL AND TRANSPLANT PROCEDURES TO SUPPORT GROWTH OF APHERESIS
 
 
 
 
 
 
4.2.1.4
TECHNOLOGICAL IMPROVEMENTS IN COMPONENT-SPECIFIC BLOOD COLLECTION TO SUPPORT MARKET EXPANSION
 
 
 
 
 
 
4.2.1.5
EXPANDING ADOPTION OF CELL AND GENE THERAPIES TO CREATE GROWTH OPPORTUNITIES FOR APHERESIS MARKET
 
 
 
 
 
4.2.2
RESTRAINTS
 
 
 
 
 
 
 
4.2.2.1
HIGH PROCEDURAL AND OPERATIONAL COSTS LIMIT ADOPTION OF APHERESIS TECHNOLOGIES
 
 
 
 
 
 
4.2.2.2
LIMITED ADOPTION OF APHERESIS DONATION PROCEDURES IN EMERGING ECONOMIES
 
 
 
 
 
 
4.2.2.3
STRINGENT DONOR ELIGIBILITY CRITERIA AND LIMITED DONOR AVAILABILITY TO RESTRAIN APHERESIS PROCEDURES
 
 
 
 
 
 
4.2.2.4
DEARTH OF SKILLED PROFESSIONALS IMPACTING ADOPTION OF APHERESIS PROCEDURES
 
 
 
 
 
4.2.3
OPPORTUNITIES
 
 
 
 
 
 
 
4.2.3.1
ADOPTION OF APHERESIS PROCEDURES IN LEUKEMIA AND PEDIATRIC PATIENTS CREATING GROWTH OPPORTUNITIES
 
 
 
 
 
 
4.2.3.2
GROWING INVESTMENTS IN EMERGING MARKETS BY GOVERNMENTS AND KEY INDUSTRY PLAYERS
 
 
 
 
 
4.2.4
CHALLENGES
 
 
 
 
 
 
 
4.2.4.1
RISK OF PROCEDURE-RELATED ADVERSE EVENTS AND DONOR SAFETY CONCERNS
 
 
 
 
 
 
4.2.4.2
RISK OF TRANSFUSION-TRANSMITTED INFECTIONS AND INADEQUATE BLOOD SCREENING INFRASTRUCTURE IN EMERGING COUNTRIES
 
 
 
 
4.3
UNMET NEEDS AND WHITE SPACES
 
 
 
 
 
 
 
4.3.1
UNMET NEEDS IN APHERESIS MARKET
 
 
 
 
 
 
4.3.2
WHITE SPACE OPPORTUNITIES
 
 
 
 
 
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
 
 
 
 
 
 
 
4.4.1
INTERCONNECTED MARKETS
 
 
 
 
 
 
4.4.2
CROSS-SECTOR OPPORTUNITIES
 
 
 
 
 
4.5
STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
 
 
 
 
 
 
 
4.5.1
STRATEGIC MOVES IN APHERESIS MARKET
 
 
 
 
5
INDUSTRY TRENDS
Uncover strategic shifts as global healthcare trends reshape competitive dynamics and supply chains.
 
 
 
 
 
60
 
5.1
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
 
5.1.1
THREAT FROM NEW ENTRANTS
 
 
 
 
 
 
5.1.2
THREAT FROM SUBSTITUTES
 
 
 
 
 
 
5.1.3
BARGAINING POWER OF SUPPLIERS
 
 
 
 
 
 
5.1.4
BARGAINING POWER OF BUYERS
 
 
 
 
 
 
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
 
 
5.2
MACROECONOMIC INDICATORS
 
 
 
 
 
 
 
5.2.1
INTRODUCTION
 
 
 
 
 
 
5.2.2
GDP TRENDS AND FORECAST
 
 
 
 
 
 
5.2.3
TRENDS IN GLOBAL HEALTHCARE INDUSTRY
 
 
 
 
 
 
5.2.4
TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY
 
 
 
 
 
5.3
SUPPLY CHAIN ANALYSIS
 
 
 
 
 
 
 
5.4
VALUE CHAIN ANALYSIS
 
 
 
 
 
 
 
5.5
ECOSYSTEM ANALYSIS
 
 
 
 
 
 
 
 
5.5.1
MANUFACTURERS
 
 
 
 
 
 
5.5.2
END USERS
 
 
 
 
 
 
5.5.3
REGULATORY BODIES
 
 
 
 
 
5.6
PRICING ANALYSIS
 
 
 
 
 
 
 
5.7
TRADE ANALYSIS
 
 
 
 
 
 
 
 
5.7.1
IMPORT DATA (HS CODE 901890)
 
 
 
 
 
 
5.7.2
EXPORT DATA FOR (HS CODE 901890)
 
 
 
 
 
5.8
REIMBURSEMENT SCENARIO
 
 
 
 
 
 
5.9
KEY CONFERENCES & EVENTS, 2026–2027
 
 
 
 
 
 
5.10
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
 
 
 
 
 
 
5.11
INVESTMENT & FUNDING SCENARIO
 
 
 
 
 
 
 
5.12
CASE STUDY ANALYSIS
 
 
 
 
 
 
5.13
IMPACT OF 2025 US TARIFF
 
 
 
 
 
 
 
 
5.13.1
INTRODUCTION
 
 
 
 
 
 
5.13.2
KEY TARIFF RATES
 
 
 
 
 
 
5.13.3
PRICE IMPACT ANALYSIS
 
 
 
 
 
 
5.13.4
IMPACT ON COUNTRY/REGION
 
 
 
 
 
 
5.13.5
IMPACT ON END-USE SEGMENTS
 
 
 
 
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
AI-driven innovations revolutionize apheresis with real-time monitoring and automated workflows for personalized therapy.
 
 
 
 
 
82
 
6.1
TECHNOLOGY ANALYSIS
 
 
 
 
 
 
 
6.1.1
KEY EMERGING TECHNOLOGIES
 
 
 
 
 
 
 
6.1.1.1
AUTOMATION AND AI-ENABLED PROCEDURE OPTIMIZATION IN APHERESIS SYSTEMS
 
 
 
 
 
 
6.1.1.2
CLOSED-LOOP AND AUTOMATED CELL THERAPY COLLECTION/MANUFACTURING WORKFLOWS
 
 
 
 
 
6.1.2
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
 
 
 
6.1.2.1
REAL-TIME BIOSENSORS AND DIGITAL MONITORING IN APHERESIS PROCEDURES
 
 
 
 
 
 
6.1.2.2
RFID, BARCODE, AND DIGITAL TRACEABILITY TECHNOLOGIES IN BLOOD AND CELL COLLECTION MANAGEMENT
 
 
 
 
 
6.1.3
ADJACENT TECHNOLOGIES
 
 
 
 
 
 
 
6.1.3.1
CELL AND GENE THERAPY MANUFACTURING TECHNOLOGIES
 
 
 
 
 
 
6.1.3.2
THERAPEUTIC FILTRATION, ADSORPTION, AND EXTRACORPOREAL BLOOD PURIFICATION TECHNOLOGIES
 
 
 
 
6.2
TECHNOLOGY/PRODUCT ROADMAP
 
 
 
 
 
 
 
6.2.1
NEAR TERM (2025–2027)
 
 
 
 
 
 
6.2.2
MID-TERM (2028–2030)
 
 
 
 
 
 
6.2.3
LONG TERM (2030+)
 
 
 
 
 
6.3
PATENT ANALYSIS
 
 
 
 
 
 
 
 
6.3.1
JURISDICTION AND TOP APPLICANT ANALYSIS
 
 
 
 
 
6.4
FUTURE APPLICATIONS
 
 
 
 
 
 
 
6.4.1
AI-ENABLED AND DATA-DRIVEN APHERESIS PROCEDURE OPTIMIZATION
 
 
 
 
 
 
6.4.2
PERSONALIZED THERAPEUTIC APHERESIS
 
 
 
 
 
 
6.4.3
CONNECTED APHERESIS WORKFLOWS AND DIGITAL TRACEABILITY
 
 
 
 
 
6.5
IMPACT OF AI/GEN AI ON APHERESIS
 
 
 
 
 
 
 
 
6.5.1
INTRODUCTION
 
 
 
 
 
 
6.5.2
MARKET POTENTIAL OF AI IN APHERESIS
 
 
 
 
 
 
6.5.3
AI USE CASES
 
 
 
 
 
 
6.5.4
KEY COMPANIES IMPLEMENTING AI
 
 
 
 
7
SUSTAINABILITY & REGULATORY LANDSCAPE
Navigate global sustainability regulations to reduce apheresis waste using eco-friendly materials.
 
 
 
 
 
93
 
7.1
REGULATORY LANDSCAPE
 
 
 
 
 
 
 
7.1.1
REGULATORY FRAMEWORK
 
 
 
 
 
 
 
7.1.1.1
NORTH AMERICA
 
 
 
 
 
 
7.1.1.2
EUROPE
 
 
 
 
 
 
7.1.1.3
ASIA PACIFIC
 
 
 
 
 
 
7.1.1.4
LATIN AMERICA
 
 
 
 
 
 
7.1.1.5
MIDDLE EAST & AFRICA
 
 
 
 
 
7.1.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
7.1.3
INDUSTRY STANDARDS
 
 
 
 
 
7.2
SUSTAINABILITY INITIATIVES
 
 
 
 
 
 
 
7.2.1
REDUCING SINGLE-USE APHERESIS WASTE
 
 
 
 
 
 
7.2.2
USE OF LOWER-IMPACT MATERIALS AND PACKAGING
 
 
 
 
 
 
7.2.3
CERTIFICATIONS, LABELING, AND ECO-STANDARDS
 
 
 
 
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Identify unmet needs and key buying criteria to unlock apheresis market profitability.
 
 
 
 
 
100
 
8.1
KEY STAKEHOLDERS & BUYING CRITERIA
 
 
 
 
 
 
 
 
8.1.1
KEY STAKEHOLDERS IN BUYING PROCESS
 
 
 
 
 
 
8.1.2
BUYING CRITERIA
 
 
 
 
 
8.2
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
 
 
 
 
 
 
 
8.2.1
DECISION-MAKING PROCESS
 
 
 
 
 
 
8.2.2
ADOPTION BARRIERS & INTERNAL CHALLENGES
 
 
 
 
 
 
8.2.3
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
 
 
 
 
 
 
8.2.4
MARKET PROFITABILITY
 
 
 
 
9
APHERESIS MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 11 Data Tables
 
 
 
 
 
105
 
9.1
INTRODUCTION
 
 
 
 
 
 
9.2
DONOR APHERESIS
 
 
 
 
 
 
 
9.2.1
INCREASING BLOOD DONATIONS AND EXPANDING CELL THERAPY COLLECTIONS TO SUPPORT DONOR APHERESIS MARKET GROWTH
 
 
 
 
 
9.3
THERAPEUTIC APHERESIS
 
 
 
 
 
 
 
9.3.1
GROWING CLINICAL UTILIZATION OF THERAPEUTIC PLASMA EXCHANGE AND EXPANDING NEUROLOGICAL APPLICATIONS TO DRIVE MARKET
 
 
 
 
 
9.4
NEUROLOGICAL DISORDERS
 
 
 
 
 
 
 
9.4.1
GROWING BURDEN OF NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH
 
 
 
 
 
9.5
BLOOD DISORDERS
 
 
 
 
 
 
 
9.5.1
RISING PREVALENCE OF HEMATOLOGICAL AND GENETIC BLOOD DISORDERS TO DRIVE DEMAND
 
 
 
 
 
9.6
RENAL DISORDERS
 
 
 
 
 
 
 
9.6.1
RISING BURDEN OF CHRONIC KIDNEY DISEASE AND AUTOIMMUNE RENAL COMPLICATIONS TO DRIVE DEMAND
 
 
 
 
 
9.7
AUTOIMMUNE DISORDERS
 
 
 
 
 
 
 
9.7.1
INCREASING PREVALENCE OF AUTOIMMUNE DISORDERS AND CONTINUED CLINICAL IMPORTANCE OF THERAPEUTIC APHERESIS TO DRIVE GROWTH
 
 
 
 
 
9.8
METABOLIC DISORDERS
 
 
 
 
 
 
 
9.8.1
GROWING BURDEN OF DIABETES AND METABOLIC CONDITIONS TO SUPPORT THERAPEUTIC APHERESIS MARKET GROWTH
 
 
 
 
 
9.9
CARDIOVASCULAR DISORDERS
 
 
 
 
 
 
 
9.9.1
RISING LONG-TERM BURDEN OF CARDIOVASCULAR DISORDERS TO DRIVE MARKET GROWTH
 
 
 
 
 
9.10
OTHER DISORDERS
 
 
 
 
 
10
APHERESIS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 4 Data Tables
 
 
 
 
 
122
 
10.1
INTRODUCTION
 
 
 
 
 
 
10.2
BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS
 
 
 
 
 
 
 
10.2.1
INCREASING DEMAND FOR COMPONENT-SPECIFIC BLOOD COLLECTION AND COMMERCIAL PLASMA SUPPLY TO DRIVE MARKET GROWTH
 
 
 
 
 
10.3
HOSPITALS & TRANSFUSION CENTERS
 
 
 
 
 
 
 
10.3.1
EXPANDING TRANSFUSION REQUIREMENTS IN ONCOLOGY, TRANSPLANT, AND CRITICAL CARE SETTINGS TO DRIVE MARKET GROWTH
 
 
 
 
 
10.4
OTHER END USERS
 
 
 
 
 
11
APHERESIS MARKET, BY PROCEDURE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 7 Data Tables
 
 
 
 
 
128
 
11.1
INTRODUCTION
 
 
 
 
 
 
11.2
PLASMAPHERESIS
 
 
 
 
 
 
 
11.2.1
INCREASING GLOBAL DEMAND FOR PLASMA-DERIVED THERAPIES AND THERAPEUTIC PLASMA EXCHANGE TO DRIVE MARKET GROWTH
 
 
 
 
 
11.3
PLATELETAPHERESIS
 
 
 
 
 
 
 
11.3.1
INCREASING DEMAND FOR PLATELET TRANSFUSIONS IN ONCOLOGY, TRANSPLANT, AND CRITICAL CARE SETTINGS TO DRIVE MARKET GROWTH
 
 
 
 
 
11.4
ERYTHROCYTAPHERESIS
 
 
 
 
 
 
 
11.4.1
INCREASING BURDEN OF SICKLE CELL DISEASE AND RISING DEMAND FOR TARGETED RED BLOOD CELL EXCHANGE PROCEDURES TO DRIVE GROWTH
 
 
 
 
 
11.5
LEUKAPHERESIS
 
 
 
 
 
 
 
11.5.1
EXPANDING CELL AND GENE THERAPY PIPELINE AND INCREASING CAR-T CELL MANUFACTURING ACTIVITIES TO DRIVE MARKET GROWTH
 
 
 
 
 
11.6
PHOTOPHERESIS
 
 
 
 
 
 
 
11.6.1
INCREASING TRANSPLANT PROCEDURES AND RISING USE OF IMMUNE-MODULATING THERAPIES TO SUPPORT MARKET GROWTH
 
 
 
 
 
11.7
OTHER PROCEDURES
 
 
 
 
 
12
APHERESIS MARKET, BY PRODUCT
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million and Units | 6 Data Tables
 
 
 
 
 
141
 
12.1
INTRODUCTION
 
 
 
 
 
 
12.2
APHERESIS DEVICES
 
 
 
 
 
 
 
12.2.1
RISING DEMAND FOR PLASMA-DERIVED THERAPIES TO DRIVE SEGMENT GROWTH
 
 
 
 
 
12.3
APHERESIS DISPOSABLES
 
 
 
 
 
 
 
12.3.1
RECURRING UTILIZATION OF SINGLE-USE CONSUMABLES AND RISING THERAPEUTIC PROCEDURE VOLUMES TO DRIVE GROWTH
 
 
 
 
13
APHERESIS MARKET, BY TECHNOLOGY
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 8 Data Tables
 
 
 
 
 
147
 
13.1
INTRODUCTION
 
 
 
 
 
 
13.2
CENTRIFUGATION
 
 
 
 
 
 
13.3
CONTINUOUS FLOW CENTRIFUGATION
 
 
 
 
 
 
 
13.3.1
INCREASING NEED FOR HIGH-THROUGHPUT BLOOD COMPONENT COLLECTION AND EFFICIENT PLASMA PROCESSING TO DRIVE GROWTH
 
 
 
 
 
13.4
INTERMITTENT FLOW CENTRIFUGATION
 
 
 
 
 
 
 
13.4.1
INCREASING DEMAND FOR COST-EFFECTIVE AND FLEXIBLE APHERESIS SYSTEMS IN HEALTHCARE SETTINGS TO SUPPORT MARKET GROWTH
 
 
 
 
 
13.5
MEMBRANE SEPARATION
 
 
 
 
 
 
 
13.5.1
INCREASING UTILIZATION OF MEMBRANE-BASED PLASMA FILTRATION TECHNOLOGIES IN THERAPEUTIC APHERESIS TO DRIVE MARKET GROWTH
 
 
 
 
14
APHERESIS MARKET, BY REGION
Comprehensive coverage of 8 Regions with country-level deep-dive of 21 Countries | 187 Data Tables.
 
 
 
 
 
156
 
14.1
INTRODUCTION
 
 
 
 
 
 
14.2
NORTH AMERICA
 
 
 
 
 
 
 
14.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
 
 
 
 
 
 
14.2.2
US
 
 
 
 
 
 
 
14.2.2.1
STRONG ECONOMIC CAPACITY AND HIGH HEALTHCARE SPENDING TO SUPPORT NORTH AMERICA APHERESIS MARKET GROWTH
 
 
 
 
 
14.2.3
CANADA
 
 
 
 
 
 
 
14.2.3.1
RISING DEMAND FOR BLOOD COMPONENTS AND PLASMA PROTEIN PRODUCTS TO DRIVE MARKET GROWTH
 
 
 
 
14.3
ASIA PACIFIC
 
 
 
 
 
 
 
14.3.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
 
 
 
 
 
 
14.3.2
CHINA
 
 
 
 
 
 
 
14.3.2.1
EXPANDING HEALTHCARE INFRASTRUCTURE AND GROWING DEMAND FOR ADVANCED BLOOD MANAGEMENT PROCEDURES TO ACCELERATE GROWTH
 
 
 
 
 
14.3.3
JAPAN
 
 
 
 
 
 
 
14.3.3.1
AGING-DRIVEN TREATMENT DEMAND AND ADVANCED HOSPITAL INFRASTRUCTURE TO SUPPORT MARKET GROWTH
 
 
 
 
 
14.3.4
INDIA
 
 
 
 
 
 
 
14.3.4.1
LARGE PATIENT BASE AND EXPANDING HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET
 
 
 
 
 
14.3.5
AUSTRALIA
 
 
 
 
 
 
 
14.3.5.1
STRONG HEALTHCARE INFRASTRUCTURE AND GROWING DEMAND FOR SPECIALIZED THERAPIES TO SUPPORT MARKET GROWTH
 
 
 
 
 
14.3.6
SOUTH KOREA
 
 
 
 
 
 
 
14.3.6.1
ADVANCED HEALTHCARE TECHNOLOGIES AND GROWING SPECIALTY CARE ADOPTION TO SUPPORT MARKET GROWTH
 
 
 
 
 
14.3.7
THAILAND
 
 
 
 
 
 
 
14.3.7.1
EXPANDING SPECIALTY CARE INFRASTRUCTURE AND RISING CHRONIC DISEASE BURDEN TO SUPPORT MARKET GROWTH
 
 
 
 
 
14.3.8
SINGAPORE
 
 
 
 
 
 
 
14.3.8.1
ADVANCED HEALTHCARE INFRASTRUCTURE AND REGIONAL MEDICAL HUB STATUS TO SUPPORT MARKET GROWTH
 
 
 
 
 
14.3.9
REST OF ASIA PACIFIC
 
 
 
 
 
14.4
EUROPE
 
 
 
 
 
 
 
14.4.1
MACROECONOMIC OUTLOOK FOR EUROPE
 
 
 
 
 
 
14.4.2
GERMANY
 
 
 
 
 
 
 
14.4.2.1
HIGH HEALTHCARE SPENDING AND STRONG REIMBURSEMENT SUPPORT TO DRIVE MARKET GROWTH
 
 
 
 
 
14.4.3
FRANCE
 
 
 
 
 
 
 
14.4.3.1
CENTRALIZED HEALTHCARE SYSTEM AND GROWING THERAPEUTIC APHERESIS UTILIZATION TO PROPEL GROWTH
 
 
 
 
 
14.4.4
ITALY
 
 
 
 
 
 
 
14.4.4.1
RISING ELDERLY POPULATION AND GROWING DEMAND FOR THERAPEUTIC PROCEDURES TO DRIVE GROWTH
 
 
 
 
 
14.4.5
UK
 
 
 
 
 
 
 
14.4.5.1
EXPANDING APHERESIS INFRASTRUCTURE AND SPECIALIZED CARE SERVICES TO SUPPORT MARKET GROWTH
 
 
 
 
 
14.4.6
SPAIN
 
 
 
 
 
 
 
14.4.6.1
GROWING CHRONIC DISEASE BURDEN AND EXPANDING SPECIALTY TREATMENT CENTERS TO SUPPORT MARKET GROWTH
 
 
 
 
 
14.4.7
SWITZERLAND
 
 
 
 
 
 
 
14.4.7.1
ADVANCED HEALTHCARE FUNDING AND SPECIALIZED TREATMENT CAPABILITIES TO SUPPORT GROWTH
 
 
 
 
 
14.4.8
NETHERLANDS
 
 
 
 
 
 
 
14.4.8.1
ADVANCED HEALTHCARE INFRASTRUCTURE AND STRONG ACADEMIC NETWORK TO SUPPORT MARKET
 
 
 
 
 
14.4.9
REST OF EUROPE
 
 
 
 
 
14.5
LATIN AMERICA
 
 
 
 
 
 
 
14.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
 
 
 
 
 
 
14.5.2
BRAZIL
 
 
 
 
 
 
 
14.5.2.1
CANCER BURDEN, BLOOD DONATION RECOVERY, AND CAR-T ACCESS TO STRENGTHEN MARKET GROWTH
 
 
 
 
 
14.5.3
MEXICO
 
 
 
 
 
 
 
14.5.3.1
EXPANDING LEUKEMIA TREATMENT ACCESS AND RISING BLOOD COMPONENT DEMAND TO SUPPORT MARKET GROWTH
 
 
 
 
 
14.5.4
REST OF LATIN AMERICA
 
 
 
 
 
14.6
MIDDLE EAST & AFRICA
 
 
 
 
 
 
 
14.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
 
 
 
 
 
 
14.6.2
GCC COUNTRIES
 
 
 
 
 
 
 
14.6.2.1
EXPANDING ADVANCED HEALTHCARE INFRASTRUCTURE AND CELL THERAPY CAPABILITIES TO SUPPORT MARKET
 
 
 
 
 
14.6.3
KINGDOM OF SAUDI ARABIA (KSA)
 
 
 
 
 
 
 
14.6.3.1
EXPANDING CELL THERAPY INFRASTRUCTURE AND CLINICAL TRIAL ECOSYSTEM TO SUPPORT MARKET GROWTH
 
 
 
 
 
 
14.6.3.2
UNITED ARAB EMIRATES (UAE)
 
 
 
 
 
 
 
 
14.6.3.2.1
GROWING PRECISION MEDICINE INITIATIVES AND ADVANCED ONCOLOGY CAPABILITIES TO SUPPORT MARKET GROWTH
 
 
 
14.6.4
OTHER GCC COUNTRIES
 
 
 
 
 
 
14.6.5
REST OF MIDDLE EAST & AFRICA
 
 
 
 
15
COMPETITIVE LANDSCAPE
Discover strategic shifts and market shares shaping the apheresis competitive landscape through 2025.
 
 
 
 
 
232
 
15.1
INTRODUCTION
 
 
 
 
 
 
15.2
KEY PLAYER STRATEGY/RIGHT TO WIN, 2023–2026
 
 
 
 
 
 
 
15.2.1
OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN APHERESIS MARKET
 
 
 
 
 
15.3
REVENUE ANALYSIS, 2023–2025
 
 
 
 
 
 
 
15.4
GLOBAL MARKET SHARE ANALYSIS, 2025
 
 
 
 
 
 
 
 
15.4.1
US: MARKET SHARE ANALYSIS, 2025
 
 
 
 
 
 
15.4.2
EUROPE: MARKET SHARE ANALYSIS, 2025
 
 
 
 
 
15.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
 
 
 
 
 
 
 
 
15.5.1
STARS
 
 
 
 
 
 
15.5.2
EMERGING LEADERS
 
 
 
 
 
 
15.5.3
PERVASIVE PLAYERS
 
 
 
 
 
 
15.5.4
PARTICIPANTS
 
 
 
 
 
 
15.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2025
 
 
 
 
 
 
 
15.5.5.1
COMPANY FOOTPRINT
 
 
 
 
 
 
15.5.5.2
REGION FOOTPRINT
 
 
 
 
 
 
15.5.5.3
PRODUCT FOOTPRINT
 
 
 
 
 
 
15.5.5.4
TYPE FOOTPRINT
 
 
 
 
 
 
15.5.5.5
TECHNOLOGY FOOTPRINT
 
 
 
 
15.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
 
 
 
 
 
 
 
 
15.6.1
PROGRESSIVE COMPANIES
 
 
 
 
 
 
15.6.2
RESPONSIVE COMPANIES
 
 
 
 
 
 
15.6.3
DYNAMIC COMPANIES
 
 
 
 
 
 
15.6.4
STARTING BLOCKS
 
 
 
 
 
 
15.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
 
 
 
 
 
15.7
COMPANY VALUATION AND FINANCIAL METRICS
 
 
 
 
 
 
 
15.7.1
FINANCIAL METRICS
 
 
 
 
 
 
15.7.2
COMPANY VALUATION
 
 
 
 
 
15.8
BRAND/PRODUCT COMPARISON
 
 
 
 
 
 
 
15.9
COMPETITIVE SCENARIO
 
 
 
 
 
 
 
15.9.1
PRODUCT LAUNCHES & APPROVALS
 
 
 
 
 
 
15.9.2
DEALS
 
 
 
 
 
 
15.9.3
EXPANSIONS
 
 
 
 
16
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
 
 
 
 
 
251
 
16.1
KEY PLAYERS (APHERESIS PRODUCTS MARKET)
 
 
 
 
 
 
 
16.1.1
TERUMO CORPORATION
 
 
 
 
 
 
 
16.1.1.1
BUSINESS OVERVIEW
 
 
 
 
 
 
16.1.1.2
PRODUCTS OFFERED
 
 
 
 
 
 
16.1.1.3
RECENT DEVELOPMENTS
 
 
 
 
 
 
 
 
16.1.1.3.1
PRODUCT LAUNCHES & APPROVALS
 
 
 
 
 
 
16.1.1.3.2
DEALS
 
 
 
 
 
 
16.1.1.3.3
EXPANSIONS
 
 
 
 
16.1.1.4
MNM VIEW
 
 
 
 
 
 
 
 
16.1.1.4.1
RIGHT TO WIN
 
 
 
 
 
 
16.1.1.4.2
STRATEGIC CHOICES
 
 
 
 
 
 
16.1.1.4.3
WEAKNESSES & COMPETITIVE THREATS
 
 
 
16.1.2
FRESENIUS SE & CO. KGAA
 
 
 
 
 
 
16.1.3
FRESENIUS MEDICAL CARE AG
 
 
 
 
 
 
16.1.4
HAEMONETICS CORPORATION
 
 
 
 
 
 
16.1.5
B. BRAUN SE
 
 
 
 
 
 
16.1.6
BD
 
 
 
 
 
 
16.1.7
ASAHI KASEI MEDICAL CO., LTD.
 
 
 
 
 
 
16.1.8
OTSUKA HOLDINGS CO., LTD.
 
 
 
 
 
 
16.1.9
MEDICA S.P.A
 
 
 
 
 
 
16.1.10
SUMITOMO BAKELITE CO., LTD.
 
 
 
 
 
 
16.1.11
KANEKA CORPORATION
 
 
 
 
 
 
16.1.12
VANTIVE
 
 
 
 
 
 
16.1.13
MILTENYI BIOTEC
 
 
 
 
 
 
16.1.14
NIKKISO CO., LTD.
 
 
 
 
 
 
16.1.15
TORAY INDUSTRIES, INC.
 
 
 
 
 
16.2
OTHER PLAYERS
 
 
 
 
 
 
 
16.2.1
MACOPHARMA SA
 
 
 
 
 
 
16.2.2
INFOMED SA
 
 
 
 
 
 
16.2.3
THERAKOS LLC.
 
 
 
 
 
 
16.2.4
MEDICAP GMBH
 
 
 
 
 
 
16.2.5
HAIER BIOMEDICAL
 
 
 
 
 
 
16.2.6
SICHUAN NIGALE BIOTECHNOLOGY CO, LTD.
 
 
 
 
 
 
16.2.7
JAFRON BIOMEDICAL CO., LTD.
 
 
 
 
 
 
16.2.8
SHANGHAI DAHUA MEDICAL APPARATUS CO., LTD
 
 
 
 
 
 
16.2.9
KENTEC MEDICAL
 
 
 
 
 
 
16.2.10
SCINOMED LTD.
 
 
 
 
17
RESEARCH METHODOLOGY
 
 
 
 
 
307
 
17.1
RESEARCH DATA
 
 
 
 
 
 
 
17.1.1
SECONDARY DATA
 
 
 
 
 
 
 
17.1.1.1
KEY DATA FROM SECONDARY SOURCES
 
 
 
 
 
17.1.2
PRIMARY DATA
 
 
 
 
 
 
 
17.1.2.1
KEY INDUSTRY INSIGHTS
 
 
 
 
17.2
MARKET SIZE ESTIMATION METHODOLOGY
 
 
 
 
 
 
17.3
MARKET GROWTH RATE PROJECTIONS
 
 
 
 
 
 
17.4
DATA TRIANGULATION
 
 
 
 
 
 
17.5
RESEARCH ASSUMPTIONS
 
 
 
 
 
 
 
17.5.1
GROWTH RATE ASSUMPTIONS
 
 
 
 
 
17.6
RISK ASSESSMENT
 
 
 
 
 
 
17.7
LIMITATIONS
 
 
 
 
 
 
 
17.7.1
METHODOLOGY-RELATED LIMITATIONS
 
 
 
 
 
 
17.7.2
SCOPE-RELATED LIMITATIONS
 
 
 
 
 
17.8
RESEARCH LIMITATIONS
 
 
 
 
 
 
17.9
RISK ANALYSIS
 
 
 
 
 
18
APPENDIX
 
 
 
 
 
321
 
18.1
DISCUSSION GUIDE
 
 
 
 
 
 
18.2
KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
 
 
18.3
CUSTOMIZATION OPTIONS
 
 
 
 
 
 
 
18.3.1
COMPANY INFORMATION
 
 
 
 
 
 
18.3.2
COUNTRY ANALYSIS
 
 
 
 
 
 
18.3.3
REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS
 
 
 
 
 
 
18.3.4
COUNTRY-LEVEL VOLUME ANALYSIS
 
 
 
 
 
 
18.3.5
ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST
 
 
 
 
 
18.4
RELATED REPORTS
 
 
 
 
 
 
18.5
AUTHOR DETAILS
 
 
 
 
 
LIST OF TABLES
 
 
 
 
 
 
 
TABLE 1
CURRENCY CONVERSION RATES, 2023–2026
 
 
 
 
 
 
TABLE 2
INDICATIVE BLOOD AND BLOOD COMPONENT UTILIZATION ACROSS MAJOR SURGICAL AND CLINICAL CONDITIONS
 
 
 
 
 
 
TABLE 3
ESTIMATED BLOOD DONATIONS, BY REGION, 2024–2025
 
 
 
 
 
 
TABLE 4
FREQUENCY OF BLOOD DONATIONS FROM HEALTHY DONORS
 
 
 
 
 
 
TABLE 5
RECENT INVESTMENTS AND STRATEGIC ACTIVITIES IN CELL & GENE THERAPY ECOSYSTEM
 
 
 
 
 
 
TABLE 6
APHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
TABLE 7
GDP CHANGE, BY KEY COUNTRY, 2021–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 8
LIST OF KEY APHERESIS MANUFACTURERS
 
 
 
 
 
 
TABLE 9
LIST OF KEY END USERS
 
 
 
 
 
 
TABLE 10
LIST OF KEY REGULATORY BODIES
 
 
 
 
 
 
TABLE 11
AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2023–2025 (USD)
 
 
 
 
 
 
TABLE 12
AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 (USD)
 
 
 
 
 
 
TABLE 13
IMPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
 
 
 
 
 
 
TABLE 14
EXPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
 
 
 
 
 
 
TABLE 15
KEY US BILLING CODES USED FOR APHERESIS PROCEDURES
 
 
 
 
 
 
TABLE 16
US AVERAGE MEDICARE OUTPATIENT PAYMENT
 
 
 
 
 
 
TABLE 17
APHERESIS MARKET: MAJOR CONFERENCES & EVENTS, 2026–2027
 
 
 
 
 
 
TABLE 18
FRESENIUS SE & CO. KGAA AMICUS APHERESIS DEVICE — THERAPEUTIC APHERESIS IN MYASTHENIA GRAVIS PATIENT
 
 
 
 
 
 
TABLE 19
TERUMO BCT’S SPECTRA OPTIA APHERESIS DEVICE — SWITCH FROM MANUAL TO AUTOMATED RED BLOOD CELL EXCHANGE IN BRAZIL
 
 
 
 
 
 
TABLE 20
TERUMO BCT + BOSTON CHILDREN’S HOSPITAL — OPTIMIZING STEM CELL COLLECTION IN SICKLE CELL DISEASE
 
 
 
 
 
 
TABLE 21
RECIPROCAL TARIFF RATES ADJUSTED BY US, 2024
 
 
 
 
 
 
TABLE 22
KEY PRODUCT-RELATED TARIFF
 
 
 
 
 
 
TABLE 23
NORTH AMERICA: IMPACT OF US TARIFF ON CANADA
 
 
 
 
 
 
TABLE 24
ASIA PACIFIC: IMPACT OF US TARIFF ON CHINA, JAPAN, AND INDIA
 
 
 
 
 
 
TABLE 25
EUROPE: IMPACT OF US TARIFF ON GERMANY AND UK
 
 
 
 
 
 
TABLE 26
LATIN AMERICA: IMPACT OF US TARIFF ON MEXICO
 
 
 
 
 
 
TABLE 27
APHERESIS MARKET: KEY PATENTS, 2023–2025
 
 
 
 
 
 
TABLE 28
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 29
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 30
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 31
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 32
MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 33
INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF APHERESIS
 
 
 
 
 
 
TABLE 34
KEY BUYING CRITERIA FOR APHERESIS PRODUCTS, BY END USER
 
 
 
 
 
 
TABLE 35
APHERESIS MARKET: ADOPTION BARRIERS & INTERNAL CHALLENGES
 
 
 
 
 
 
TABLE 36
APHERESIS MARKET: UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
 
 
 
 
 
 
TABLE 37
APHERESIS MARKET: KEY PROFITABILITY DRIVERS
 
 
 
 
 
 
TABLE 38
APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 39
DONOR APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 40
THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 41
THERAPEUTIC APHERESIS MARKET, BY DISEASE TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 42
NEUROLOGICAL DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 43
BLOOD DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 44
RENAL DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 45
AUTOIMMUNE DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 46
METABOLIC DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 47
CARDIOVASCULAR DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 48
OTHER DISORDERS: THERAPEUTIC APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 49
APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 50
BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 51
HOSPITALS & TRANSFUSION CENTERS APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 52
OTHER END USERS: APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 53
APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 54
PLASMAPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 55
PLATELETAPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 56
ERYTHROCYTAPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 57
LEUKAPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 58
PHOTOPHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 59
OTHER PROCEDURES: APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 60
APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 61
APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS)
 
 
 
 
 
 
TABLE 62
COMMERCIAL APHERESIS DEVICES
 
 
 
 
 
 
TABLE 63
APHERESIS DEVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 64
COMMERCIAL APHERESIS DISPOSABLES
 
 
 
 
 
 
TABLE 65
APHERESIS DISPOSABLES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 66
APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 67
COMMERCIAL CENTRIFUGATION TECHNOLOGY DEVICES
 
 
 
 
 
 
TABLE 68
CENTRIFUGATION APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 69
CONTINUOUS FLOW CENTRIFUGATION: APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 70
INTERMITTENT FLOW CENTRIFUGATION: APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 71
SIZE OF BLOOD COMPONENTS
 
 
 
 
 
 
TABLE 72
COMMERCIAL MEMBRANE SEPARATION DEVICES
 
 
 
 
 
 
TABLE 73
MEMBRANE SEPARATION APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 74
APHERESIS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 75
MAJOR APHERESIS MARKET PLAYERS IN NORTH AMERICA
 
 
 
 
 
 
TABLE 76
NORTH AMERICA: APHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 77
NORTH AMERICA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 78
NORTH AMERICA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 79
NORTH AMERICA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 80
NORTH AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 81
NORTH AMERICA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 82
NORTH AMERICA: APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS)
 
 
 
 
 
 
TABLE 83
US: KEY MACROINDICATORS
 
 
 
 
 
 
TABLE 84
US: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 85
US: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 86
US: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 87
US: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 88
US: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 89
CANADA: KEY MACROINDICATORS
 
 
 
 
 
 
TABLE 90
CANADA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 91
CANADA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 92
CANADA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 93
CANADA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 94
CANADA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 95
ASIA PACIFIC: APHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 96
ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 97
ASIA PACIFIC: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 98
ASIA PACIFIC: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 99
ASIA PACIFIC: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 100
ASIA PACIFIC: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 101
ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS)
 
 
 
 
 
 
TABLE 102
CHINA: KEY MACROINDICATORS
 
 
 
 
 
 
TABLE 103
CHINA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 104
CHINA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 105
CHINA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 106
CHINA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 107
CHINA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 108
JAPAN: KEY MACROINDICATORS
 
 
 
 
 
 
TABLE 109
JAPAN: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 110
JAPAN: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 111
JAPAN: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 112
JAPAN: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 113
JAPAN: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 114
INDIA: KEY MACROINDICATORS
 
 
 
 
 
 
TABLE 115
INDIA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 116
INDIA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 117
INDIA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 118
INDIA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 119
INDIA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 120
AUSTRALIA: KEY MACROINDICATORS
 
 
 
 
 
 
TABLE 121
AUSTRALIA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 122
AUSTRALIA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 123
AUSTRALIA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 124
AUSTRALIA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 125
AUSTRALIA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 126
SOUTH KOREA: KEY MACROINDICATORS
 
 
 
 
 
 
TABLE 127
SOUTH KOREA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 128
SOUTH KOREA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 129
SOUTH KOREA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 130
SOUTH KOREA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 131
SOUTH KOREA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 132
THAILAND: KEY MACROINDICATORS
 
 
 
 
 
 
TABLE 133
THAILAND: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 134
THAILAND: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 135
THAILAND: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 136
THAILAND: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 137
THAILAND: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 138
SINGAPORE: KEY MACROINDICATORS
 
 
 
 
 
 
TABLE 139
SINGAPORE: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 140
SINGAPORE: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 141
SINGAPORE: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 142
SINGAPORE: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 143
SINGAPORE: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 144
REST OF ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 145
REST OF ASIA PACIFIC: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 146
REST OF ASIA PACIFIC: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 147
REST OF ASIA PACIFIC: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 148
REST OF ASIA PACIFIC: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 149
EUROPE: APHERESIS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 150
EUROPE: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 151
EUROPE: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 152
EUROPE: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 153
EUROPE: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 154
EUROPE: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 155
EUROPE: APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS)
 
 
 
 
 
 
TABLE 156
GERMANY: KEY MACROINDICATORS
 
 
 
 
 
 
TABLE 157
GERMANY: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 158
GERMANY: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 159
GERMANY: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 160
GERMANY: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 161
GERMANY: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 162
FRANCE: KEY MACROINDICATORS
 
 
 
 
 
 
TABLE 163
FRANCE: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 164
FRANCE: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 165
FRANCE: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 166
FRANCE: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 167
FRANCE: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 168
ITALY: KEY MACROINDICATORS
 
 
 
 
 
 
TABLE 169
ITALY: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 170
ITALY: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 171
ITALY: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 172
ITALY: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 173
ITALY: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 174
UK: KEY MACROINDICATORS
 
 
 
 
 
 
TABLE 175
UK: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 176
UK: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 177
UK: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 178
UK: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 179
UK: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 180
SPAIN: KEY MACROINDICATORS
 
 
 
 
 
 
TABLE 181
SPAIN: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 182
SPAIN: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 183
SPAIN: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 184
SPAIN: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 185
SPAIN: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 186
SWITZERLAND: KEY MACROINDICATORS
 
 
 
 
 
 
TABLE 187
SWITZERLAND: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 188
SWITZERLAND: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 189
SWITZERLAND: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 190
SWITZERLAND: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 191
SWITZERLAND: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 192
NETHERLANDS: KEY MACROINDICATORS
 
 
 
 
 
 
TABLE 193
NETHERLANDS: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 194
NETHERLANDS: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 195
NETHERLANDS: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 196
NETHERLANDS: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 197
NETHERLANDS: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 198
REST OF EUROPE: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 199
REST OF EUROPE: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 200
REST OF EUROPE: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 201
REST OF EUROPE: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 202
REST OF EUROPE: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 203
LATIN AMERICA: APHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 204
LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 205
LATIN AMERICA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 206
LATIN AMERICA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 207
LATIN AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 208
LATIN AMERICA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 209
LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS)
 
 
 
 
 
 
TABLE 210
BRAZIL: KEY MACROINDICATORS
 
 
 
 
 
 
TABLE 211
BRAZIL: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 212
BRAZIL: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 213
BRAZIL: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 214
BRAZIL: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 215
BRAZIL: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 216
MEXICO: KEY MACROINDICATORS
 
 
 
 
 
 
TABLE 217
MEXICO: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 218
MEXICO: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 219
MEXICO: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 220
MEXICO: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 221
MEXICO: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 222
REST OF LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 223
REST OF LATIN AMERICA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 224
REST OF LATIN AMERICA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 225
REST OF LATIN AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 226
REST OF LATIN AMERICA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 227
MIDDLE EAST & AFRICA: APHERESIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 228
MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 229
MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 230
MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 231
MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 232
MIDDLE EAST & AFRICA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 233
MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PRODUCT, 2024-2031 (THOUSAND UNITS)
 
 
 
 
 
 
TABLE 234
GCC COUNTRIES: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 235
GCC COUNTRIES: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 236
GCC COUNTRIES: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 237
GCC COUNTRIES: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 238
GCC COUNTRIES: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 239
KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS
 
 
 
 
 
 
TABLE 240
KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 241
KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 242
KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 243
KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 244
KINGDOM OF SAUDI ARABIA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 245
UNITED ARAB EMIRATES: KEY MACROINDICATORS
 
 
 
 
 
 
TABLE 246
UNITED ARAB EMIRATES: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 247
UNITED ARAB EMIRATES: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 248
UNITED ARAB EMIRATES: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 249
UNITED ARAB EMIRATES: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 250
UNITED ARAB EMIRATES: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 251
OTHER GCC COUNTRIES: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 252
OTHER GCC COUNTRIES: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 253
OTHER GCC COUNTRIES: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 254
OTHER GCC COUNTRIES: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 255
OTHER GCC COUNTRIES: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 256
REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 257
REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 258
REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY PROCEDURE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 259
REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 260
REST OF MIDDLE EAST & AFRICA: APHERESIS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 261
OVERVIEW OF STRATEGIES DEPLOYED BY KEY APHERESIS COMPANIES, JANUARY 2023–MAY 2026
 
 
 
 
 
 
TABLE 262
APHERESIS MARKET: DEGREE OF COMPETITION
 
 
 
 
 
 
TABLE 263
APHERESIS MARKET: REGION FOOTPRINT
 
 
 
 
 
 
TABLE 264
APHERESIS MARKET: PRODUCT FOOTPRINT
 
 
 
 
 
 
TABLE 265
APHERESIS MARKET: TYPE FOOTPRINT
 
 
 
 
 
 
TABLE 266
APHERESIS MARKET: TECHNOLOGY FOOTPRINT
 
 
 
 
 
 
TABLE 267
APHERESIS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
TABLE 268
APHERESIS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
 
 
 
 
 
 
TABLE 269
APHERESIS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026
 
 
 
 
 
 
TABLE 270
APHERESIS MARKET: DEALS, JANUARY 2023–MAY 2026
 
 
 
 
 
 
TABLE 271
APHERESIS MARKET: EXPANSIONS, JANUARY 2023–MAY 2026
 
 
 
 
 
 
TABLE 272
TERUMO CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 273
TERUMO CORPORATION: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 274
TERUMO CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026
 
 
 
 
 
 
TABLE 275
TERUMO CORPORATION: DEALS, JANUARY 2023–MAY 2026
 
 
 
 
 
 
TABLE 276
TERUMO CORPORATION: EXPANSIONS, JANUARY 2023–MARCH 2026
 
 
 
 
 
 
TABLE 277
FRESENIUS SE & CO. KGAA: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 278
FRESENIUS SE & CO. KGAA: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 279
FRESENIUS SE & CO. KGAA: PRODUCT LAUNCHES, JANUARY 2023–MARCH 2026
 
 
 
 
 
 
TABLE 280
FRESENIUS SE & CO. KGAA: DEALS, JANUARY 2023–MAY 2026
 
 
 
 
 
 
TABLE 281
FRESENIUS SE & CO. KGAA: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026
 
 
 
 
 
 
TABLE 282
FRESENIUS MEDICAL CARE AG: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 283
FRESENIUS MEDICAL CARE CORPORATION: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 284
FRESENIUS MEDICAL CARE AG: DEALS, JANUARY 2023–MAY 2026
 
 
 
 
 
 
TABLE 285
HAEMONETICS CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 286
HAEMONETICS CORPORATION: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 287
HAEMONETICS CORPORATION: PRODUCT LAUNCHES, JANUARY 2023–MARCH 2026
 
 
 
 
 
 
TABLE 288
HAEMONETICS CORPORATION: DEALS, JANUARY 2023–MAY 2026
 
 
 
 
 
 
TABLE 289
B. BRAUN SE: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 290
BD: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 291
BD: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 292
BD: DEALS, JANUARY 2023–MAY 2026
 
 
 
 
 
 
TABLE 293
BD: EXPANSIONS, JANUARY 2023–MARCH 2026
 
 
 
 
 
 
TABLE 294
ASAHI KASEI MEDICAL CO., LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 295
ASAHI KASEI MEDICAL CO., LTD.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 296
ASAHI KASEI MEDICAL CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026
 
 
 
 
 
 
TABLE 297
OTSUKA HOLDINGS CO., LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 298
OTSUKA HOLDINGS CO., LTD: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 299
MEDICA S.P.A: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 300
MEDICA S.P.A: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 301
SUMITOMO BAKELITE CO., LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 302
SUMITOMO BAKELITE CO., LTD.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 303
KANEKA CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 304
KANEKA CORPORATION: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 305
KANEKA CORPORATION: DEALS, JANUARY 2023–MAY 2026
 
 
 
 
 
 
TABLE 306
KANEKA CORPORATION: EXPANSIONS, JANUARY 2023–MARCH 2026
 
 
 
 
 
 
TABLE 307
VANTIVE: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 308
VANTIVE: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 309
VANTIVE: DEALS, JANUARY 2023–MAY 2026
 
 
 
 
 
 
TABLE 310
VANTIVE: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026
 
 
 
 
 
 
TABLE 311
MILTENYI BIOTEC: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 312
MILTENYI BIOTEC: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 313
MILTENYI BIOTEC: DEALS, JANUARY 2023–MAY 2026
 
 
 
 
 
 
TABLE 314
MILTENYI BIOTEC: EXPANSIONS, JANUARY 2023–MARCH 2026
 
 
 
 
 
 
TABLE 315
NIKKISO CO., LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 316
NIKKISO CO., LTD.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 317
NIKKISO CO., LTD: DEALS, JANUARY 2023–MAY 2026
 
 
 
 
 
 
TABLE 318
NIKKISO CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2023–MARCH 2026
 
 
 
 
 
 
TABLE 319
TORAY INDUSTRIES, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 320
TORAY INDUSTRIES, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 321
MACOPHARMA SA: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 322
INFOMED SA: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 323
THERAKOS LLC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 324
MEDICAP GMBH: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 325
HAIER BIOMEDICAL: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 326
SICHUAN NIGALE BIOTECHNOLOGY CO, LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 327
JAFRON BIOMEDICAL CO., LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 328
SHANGHAI DAHUA MEDICAL APPARATUS CO., LTD: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 329
KENTEC MEDICAL: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 330
SCINOMED LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 331
IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS ON APHERESIS MARKET
 
 
 
 
 
 
LIST OF FIGURES
 
 
 
 
 
 
 
FIGURE 1
MARKET SCENARIO
 
 
 
 
 
 
FIGURE 2
GLOBAL APHERESIS MARKET, 2024–2031
 
 
 
 
 
 
FIGURE 3
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN APHERESIS MARKET, 2023–2026
 
 
 
 
 
 
FIGURE 4
DISRUPTIONS INFLUENCING GROWTH OF APHERESIS MARKET
 
 
 
 
 
 
FIGURE 5
HIGH-GROWTH SEGMENTS, 2026–2031
 
 
 
 
 
 
FIGURE 6
ASIA PACIFIC TO REGISTER HIGHEST GROWTH, IN TERMS OF VALUE, DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 7
GROWING INCIDENCE OF CHRONIC DISEASES AND WIDER ADOPTION OF THERAPEUTIC APHERESIS TO DRIVE MARKET GROWTH
 
 
 
 
 
 
FIGURE 8
BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2025
 
 
 
 
 
 
FIGURE 9
CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 10
APHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
 
 
 
 
 
 
FIGURE 11
APHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
FIGURE 12
APHERESIS MARKET: SUPPLY CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 13
APHERESIS MARKET: VALUE CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 14
APHERESIS MARKET ECOSYSTEM
 
 
 
 
 
 
FIGURE 15
REVENUE SHIFT AND NEW REVENUE POCKETS FOR APHERESIS MARKET
 
 
 
 
 
 
FIGURE 16
INVESTMENT & FUNDING SCENARIO
 
 
 
 
 
 
FIGURE 17
TOP APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS) FOR APHERESIS PATENTS, JANUARY 2015–MAY 2026
 
 
 
 
 
 
FIGURE 18
APHERESIS MARKET: AI USE CASES
 
 
 
 
 
 
FIGURE 19
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF APHERESIS PRODUCTS
 
 
 
 
 
 
FIGURE 20
KEY BUYING CRITERIA FOR APHERESIS PRODUCTS, BY END USER
 
 
 
 
 
 
FIGURE 21
NORTH AMERICA: ESTIMATED NUMBER OF NEW CASES, 2025
 
 
 
 
 
 
FIGURE 22
NORTH AMERICA: APHERESIS MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 23
ASIA PACIFIC: APHERESIS MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 24
REVENUE ANALYSIS OF KEY PLAYERS, 2023–2025 (USD MILLION)
 
 
 
 
 
 
FIGURE 25
GLOBAL MARKET SHARE ANALYSIS, 2025
 
 
 
 
 
 
FIGURE 26
US: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025
 
 
 
 
 
 
FIGURE 27
EUROPE: MARKET SHARE ANALYSIS, 2025
 
 
 
 
 
 
FIGURE 28
APHERESIS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
 
 
 
 
 
 
FIGURE 29
APHERESIS MARKET: COMPANY FOOTPRINT
 
 
 
 
 
 
FIGURE 30
APHERESIS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
 
 
 
 
 
 
FIGURE 31
EV/EBITDA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 32
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 33
APHERESIS MARKET: BRAND/PRODUCT COMPARISON
 
 
 
 
 
 
FIGURE 34
TERUMO CORPORATION: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 35
FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 36
FRESENIUS MEDICAL CARE AG: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 37
HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 38
B. BRAUN SE: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 39
BD: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 40
OTSUKA HOLDINGS CO., LTD: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 41
SUMITOMO BAKELITE CO., LTD.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 42
KANEKA CORPORATION: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 43
NIKKISO CO., LTD.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 44
TORAY INDUSTRIES, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 45
RESEARCH DESIGN
 
 
 
 
 
 
FIGURE 46
PRIMARY SOURCES
 
 
 
 
 
 
FIGURE 47
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (SUPPLY SIDE)
 
 
 
 
 
 
FIGURE 48
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (DEMAND SIDE)
 
 
 
 
 
 
FIGURE 49
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
 
 
 
 
 
 
FIGURE 50
GLOBAL MARKET ESTIMATION: SUPPLY-SIDE ANALYSIS (BOTTOM-UP APPROACH)
 
 
 
 
 
 
FIGURE 51
APHERESIS MARKET SIZE ANALYSIS, 2025
 
 
 
 
 
 
FIGURE 52
MARKET SIZE ESTIMATION FOR APHERESIS: REVENUE SHARE ANALYSIS
 
 
 
 
 
 
FIGURE 53
MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
 
 
 
 
 
 
FIGURE 54
APHERESIS MARKET: CAGR PROJECTIONS, 2026–2031
 
 
 
 
 
 
FIGURE 55
DATA TRIANGULATION METHODOLOGY
 
 
 
 
 
 

Methodology

This study involved the extensive use of both primary and secondary sources. The research process involved examining various factors affecting the industry to identify segmentation types, industry trends, key players, the competitive landscape, key market dynamics, and key players' strategies.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, Companies House documents, investor presentations, and SEC filings. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the apheresis market. It was also used to obtain important information about key players, market classification & segmentation according to industry trends, down to the bottom level, and key developments from market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply & demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the apheresis market. The primary sources from the demand side include medical OEMs, medical device ISOs, and service providers, among others. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights into key industry trends & key market dynamics.

Apheresis Market 
 Size, and Share

Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
Note 2: Others include sales, marketing, and product managers.
Note 3: Companies are classified into tiers based on their total revenue. As of 2025, Tier 1 = >USD 2 billion, Tier 2 = USD 50 million to USD 2 billion, and Tier 3 = <USD 50 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

In this report, the global apheresis market size was determined using revenue share analysis of leading players. For this purpose, key market players were identified, and their revenues from the apheresis business were determined using insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, including CEOs, directors, and marketing executives.

To calculate the global market value, segmental revenues were derived from the revenue mapping of major solution/service providers. This process involves the following steps:

  • Generating a list of major global players operating in the apheresis market
  • Mapping annual revenues generated by major global players from the apheresis segment (or nearest reported business unit/service category)
  • Revenue mapping of key players to cover a major share of the global market as of 2025
  • Extrapolating the global value of the apheresis industry

Apheresis Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the overall market size through the market size estimation process explained above, the global apheresis market was segmented and subsegmented. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the apheresis market was validated using both top-down and bottom-up approaches.

Market Definition

Apheresis is a medical technology and extracorporeal blood separation procedure in which whole blood is withdrawn from a donor or patient and processed through a device that separates specific blood components. The desired component is collected or treated, while the remaining blood components are returned to the individual. The process primarily uses centrifugation or membrane filtration to separate blood components.

Apheresis encompasses both donor and therapeutic procedures and is widely used in transfusion medicine, hematology, oncology, nephrology, neurology, and immunology for blood component collection and the treatment of various disorders, including autoimmune diseases, hematologic conditions, and metabolic disorders.

Key Stakeholders

  • Companies manufacturing apheresis devices & disposables
  • Original equipment manufacturing companies
  • Suppliers and distributors of apheresis devices & disposables
  • Healthcare service providers
  • Health insurance payers
  • Government bodies/municipal corporations
  • Regulatory bodies
  • Medical research institutes
  • Business research and consulting service providers
  • Venture capitalists
  • Market research and consulting firms

Report Objectives

  • To define, describe, and forecast the global apheresis devices market based on product, type, procedure, technology, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth
    (such as drivers, restraints, opportunities, and challenges) along with the current trends
  • To strategically analyze micromarkets1 concerning individual growth trends, prospects, and contributions to the overall apheresis market
  • To analyze the opportunities in the global apheresis market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments concerning five main regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and analyze their market shares and core competencies2
  • To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, expansions, strategic alliances, and acquisitions in the global apheresis market.
  • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.

Available customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global apheresis market report:

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of the top twelve companies

Company Information

  • Detailed analysis and profiling of additional market players (up to 10)

Geographic Analysis

  • Further breakdown of the Rest of Europe's apheresis market into Russia, Finland, Switzerland, Turkey, the Czech Republic, the Netherlands, Norway, Poland, Portugal, Romania, Estonia, Austria, and Belgium
  • Further breakdown of the Rest of Asia Pacific’s apheresis market into Taiwan, New Zealand, and Sri Lanka
  • Further breakdown of the Rest of Latin America’s apheresis market into Uruguay, Costa Rica, Bolivia, Venezuela, and Paraguay

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Apheresis Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

TESTIMONIALS

Growth opportunities and latent adjacency in Apheresis Market

DMCA.com Protection Status